RxDoctor Payments Data

Michael Rihner, MD

Cardiovascular Disease · Mobile, ALNPI 1831279702

Payments from drug & device makers

$12,863in general payments, 2019–2025

Across 469 payments — averaging $27.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Novartis$2K
  • Johnson & Johnson$1K
  • Boehringer Ingelheim$485
  • Sanofi-aventis U.S. LLC$468
  • E.r. Squibb & Sons, L.L.C.$365
  • plus $3K from 35 others

What the payments were for

  • Consulting fees$1,26910%
  • Speaking & faculty fees$3,85030%
  • Food & beverage$7,74460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,863 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$618,793
Medicare patients
723
Services billed
4,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban559$579,611
EntrestoSacubitril/Valsartan460$568,442
EliquisApixaban251$243,493
MounjaroTirzepatide157$192,163
FarxigaDapagliflozin Propanediol112$145,182
Repatha SureclickEvolocumab94$83,874
JardianceEmpagliflozin76$83,217
Ranolazine ErRanolazine315$41,562
MultaqDronedarone Hcl20$32,538
BrilintaTicagrelor37$25,284
OzempicSemaglutide12$20,593
VascepaIcosapent Ethyl26$19,219
Atorvastatin Calcium1,305$17,021
Bisoprolol Fumarate417$14,243
Amiodarone Hcl315$10,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,425$579,611559 claims
NovartisEntresto$1,553$568,442460 claims
PfizerEliquis$95$243,493251 claims
AstraZenecaFarxiga, Brilinta$5,577$170,466149 claims
Boehringer IngelheimJardiance$485$83,21776 claims
Sanofi-aventis U.S. LLCMultaq$468$32,53820 claims
Novo NordiskOzempic$110$20,59312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →